Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
- Conditions
- Epilepsy
- Interventions
- Drug: eslicarbacepine
- Registration Number
- NCT02573272
- Lead Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Brief Summary
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 204
Inclusion Criteria
- Patients over 18 years
- patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests.
- patients with stable and identifiable antiepileptic treatment during the last two years.
- patients according to the investigator are able to provide clinical data necessary for the development of the study
- Patients who signed informed consent
Exclusion Criteria
- Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Epileptic patients with AEDs and eslicarbacepine eslicarbacepine -
- Primary Outcome Measures
Name Time Method Carotid IMT millimeters one year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital Torrecardenas
🇪🇸Almería, Almeria, Spain